Akero Therapeutics is focused on developing Efruxifermin (EFX) for the treatment of metabolic diseases, particularly MASH (Metabolic Associated Steatotic Liver Disease)
Akero Therapeutics is focused on developing Efruxifermin (EFX) for the treatment of metabolic diseases, particularly MASH (Metabolic Associated Steatotic Liver Disease).
Akero Therapeutics is focused on developing Efruxifermin (EFX) for the treatment of metabolic diseases, particularly MASH (Metabolic Associated Steatotic Liver Disease)
Akero Therapeutics is focused on developing Efruxifermin (EFX) for the treatment of metabolic diseases, particularly MASH (Metabolic Associated Steatotic Liver Disease).